Tuesday, September 1, 2026
Moderna prices upsized $2.6 billion convertible notes
Moderna said on August 28, 2026 it priced an upsized $2.6 billion private offering of 0.00% convertible senior notes due 2032, up from a planned $2.0 billion, with sale to qualified institutional buyers expected to close September 1. The notes carry an initial conversion price of about $210.58 per share, a 47.5% premium to Moderna's August 27 close, and are paired with capped call transactions capped near $392.62 per share to limit potential dilution.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.
/ Related
- FDA approves Moderna's updated 2026-2027 COVID vaccinesFriday, August 28, 2026
- Moderna to raise $2 billion in convertible senior notesThursday, August 27, 2026
- Moderna-Merck melanoma vaccine hits Phase 3 goals, shares surgeWednesday, August 19, 2026
- FDA approves Moderna's mFlusiva, the first mRNA flu vaccineMonday, August 17, 2026